XML 21 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Statements of Cash Flows - USD ($)
 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Operating activities    
Net loss $ (3,605,374) $ (12,318,110)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization and depreciation 261,679 246,791
Amortization of deferred issuance costs 192,647 101,329
Stock-based compensation 1,264,608 1,344,476
Fair value change in warrant liability (784,670) 327,092
Debt and equity facility costs reclassified to financing activities 141,416 127,659
Non-cash lease expense 111,613 113,534
Valuation adjustments for excess or obsolete inventory 10,000
Change in assets and liabilities:    
Accounts receivable (1,088,169) (176,636)
Inventory 398,348 (908,467)
Prepaid expenses 75,089 47,285
Accounts payable 239,983 66,993
Accrued expenses, operating lease and other liabilities (54,442) 16,214
Net cash used in operating activities (2,837,272) (11,011,840)
Investing activities    
Purchases of property and equipment (81,742) (120,197)
Net cash used in investing activities (81,742) (120,197)
Financing activities    
Proceeds from issuance of common stock in connection with private placement 836,777
Proceeds from issuance of warrants in connection with private placement 1,813,223
Proceeds from issuance of common stock attributed to non-private placement equity offerings 9,614,037 5,033,906
Issuance costs attributed to common stock and warrants issued in private placement (185,903) (1,320)
Issuance costs related to non-private placement equity offerings (1,045,971) (236,597)
Deferred issuance costs in connection with at-the-market offering program (20,000)
Deferred issuance costs in connection with debt facility (297,942) (75,000)
Exercise of warrants 69,750
Share repurchases for the payment of employee taxes (124,617) (81,403)
Net cash provided by financing activities 8,029,354 7,269,586
Net increase (decrease) in cash and cash equivalents 5,110,340 (3,862,451)
Cash and cash equivalents at beginning of year 1,460,042 5,322,493
Cash and cash equivalents at end of year 6,570,382 1,460,042
Supplemental non-cash financing and investing transactions:    
Modification of right-of-use asset and associated lease liability 111,898 199,385
Non-cash warrants issued in connection with debt facility 53,124
Unpaid issuance costs in connection with private placement 185,903
Unpaid deferred issuance costs $ 22,920 $ 95,837